The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.
HalioDx will perform immune biomarker exploratory work for the collaboration, which will focus on defining the profile of responder patients to Tedopi.
The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.